<DOC>
	<DOCNO>NCT00224003</DOCNO>
	<brief_summary>A phase 4 clinical investigation iron-replete pediatric hemodialysis patient , whose legal guardian provide sign informed consent , satisfied inclusion exclusion criterion study .</brief_summary>
	<brief_title>Study Safety Efficacy FerrlecitÂ® Maintenance Dosing Pediatric Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female pediatric ESRD , Patients &gt; _ 2 &lt; _ 16 year age , whose legally authorize representative provide sign informed consent . Stabilized chronic hemodialysis therapy identify need maintenance iron therapy . Predetermined TSAT serum Ferritin ( screen visit ) . Receiving stable EPO dose regimen . Receipt form iron supplementation 2 week prior first Ferrlecit dose . Hypersensitivity Ferrlecit inactive component . High TSAT level . High Serum Ferritin</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Anemia</keyword>
</DOC>